Cat. No.: HY-14166

MK-886

(Synonyms: L 663536)

13 Cited Publications

Avis client

Based on 13 publication(s) in Google Scholar

MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC₅₀ of 30 nM) and leukotriene biosynthesis (IC₅₀s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.77%
CAS No.: 118414-82-7
Formule: C₂₇H₃₄ClNO₂S
Masse moléculaire:472.08

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

MK-886 Chemical Structure

CAS No.: 118414-82-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target

IC50: 30 nM (FLAP)^[3]
IC50: 3 nM (Leukotriene biosynthesis in intact leukocytes) and 1.1 μM (Leukotriene biosynthesis in human whole blood)^[2]
PPARα^[1]

Voir tous les produits spécifiques à Isoform Leukotriene Receptor :

Voir tous les produits spécifiques à Isoform PPAR :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2 μM Compound: MK-886	Inhibition of PGES-1 in human A549 cell microsomes using PGH2 as substrate assessed as suppression of interleukin-1beta-stimulated PGE2 production incubated for 15 mins post interleukin-1beta challenge for 72 hrs by RP-HPLC analysis Inhibition of PGES-1 in human A549 cell microsomes using PGH2 as substrate assessed as suppression of interleukin-1beta-stimulated PGE2 production incubated for 15 mins post interleukin-1beta challenge for 72 hrs by RP-HPLC analysis	[PMID: 26602278]
A549	IC₅₀	2 μM Compound: 1	Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE2 Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE2	[PMID: 19884011]
A549	IC₅₀	2.1 μM Compound: 9, MK-886	Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation by cell-free assay Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation by cell-free assay	[PMID: 19053751]
A549	IC₅₀	2.1 μM Compound: MK-886	Inhibition of mPGES1 in IL-1beta treated human A549 cell microsomal membrane assessed as inhibition of PGE2 formation incubated for 15 mins before addition of PGH2 by RP-HPLC method Inhibition of mPGES1 in IL-1beta treated human A549 cell microsomal membrane assessed as inhibition of PGE2 formation incubated for 15 mins before addition of PGH2 by RP-HPLC method	[PMID: 21800856]
A549	IC₅₀	2.1 μM Compound: MK-886	Inhibition of PGES-1 in IL-1beta stimulated human A549 cell microsomes using PGH2 as substrate assessed as suppression of PGE2 formation preincubated for 15 mins followed by substrate addition by reversed phase-HPLC analysis Inhibition of PGES-1 in IL-1beta stimulated human A549 cell microsomes using PGH2 as substrate assessed as suppression of PGE2 formation preincubated for 15 mins followed by substrate addition by reversed phase-HPLC analysis	[PMID: 26777299]
A549	IC₅₀	2.11 μM Compound: 1, MK-886	Inhibition of mPGES1 in IL1-beta treated human A549 cell microsomal membrane assessed as residual enzyme activity after 1 min by measuring PGE2 level using RP-HPLC method Inhibition of mPGES1 in IL1-beta treated human A549 cell microsomal membrane assessed as residual enzyme activity after 1 min by measuring PGE2 level using RP-HPLC method	[PMID: 19719242]
A549	IC₅₀	2.2 μM Compound: 31, MK886	Inhibition of mPGES1 in IL-1beta stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 synthase activity after 15 mins using PGH2 substrate by RP-HPLC method Inhibition of mPGES1 in IL-1beta stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 synthase activity after 15 mins using PGH2 substrate by RP-HPLC method	[PMID: 25765759]
A549	IC₅₀	2.3 μM Compound: MK-886	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis	[PMID: 22992107]
A549	IC₅₀	2.4 μM Compound: 26, MK-886	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 after 15 mins Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 after 15 mins	[PMID: 21570310]
A549	IC₅₀	2.4 μM Compound: 33, MK-886	Inhibition of mPGES-1 from human A549 cell microsomal membranes using PGH2 as substrate incubated 15 mins prior to substrate addition measured after 1 min by RP-HPLC analysis Inhibition of mPGES-1 from human A549 cell microsomal membranes using PGH2 as substrate incubated 15 mins prior to substrate addition measured after 1 min by RP-HPLC analysis	[PMID: 24171493]
A549	IC₅₀	2.4 μM Compound: 36, MK-886	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis	[PMID: 21591611]
A549	IC₅₀	2.4 μM Compound: MK-886	Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	[PMID: 24844534]
A549	IC₅₀	2.4 μM Compound: MK-886	Inhibition of mPGES-1 in IL-1beta-stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 formation incubated for 15 mins using PGH2 substrate by RP-HPLC method Inhibition of mPGES-1 in IL-1beta-stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 formation incubated for 15 mins using PGH2 substrate by RP-HPLC method	[PMID: 26088337]
A549	IC₅₀	2.5 μM Compound: MK886	Inhibition of human A549 cell microsomal membrane-derived mPGES-1 assessed as reduction in conversion of PGH2 to PGE2 preincubated for 15 mins followed by PGH2 addition measured after 1 min by RP-HPLC analysis Inhibition of human A549 cell microsomal membrane-derived mPGES-1 assessed as reduction in conversion of PGH2 to PGE2 preincubated for 15 mins followed by PGH2 addition measured after 1 min by RP-HPLC analysis	[PMID: 28240894]
A549	IC₅₀	2.7 μM Compound: MK-886	Inhibition of mPGES-1 in interleukin-1 beta-stimulated human A549 cells microsomal membranes assessed as reduction in conversion of PGH2 to PGE2 pre-incubated for 15 mins followed by PGH2 substrate addition measured after 1 min by RP-HPLC method Inhibition of mPGES-1 in interleukin-1 beta-stimulated human A549 cells microsomal membranes assessed as reduction in conversion of PGH2 to PGE2 pre-incubated for 15 mins followed by PGH2 substrate addition measured after 1 min by RP-HPLC method	[PMID: 28165233]
A549	IC₅₀	3 μM Compound: MK-886	Inhibition of mPGES-1 expressed in LPS-stimulated human A549 cells mitochondrial fraction assessed as conversion of PGH2 to PGE2 Inhibition of mPGES-1 expressed in LPS-stimulated human A549 cells mitochondrial fraction assessed as conversion of PGH2 to PGE2	[PMID: 21310608]
CHO	IC₅₀	1.6 μM Compound: 13	Inhibition of human recombinant mPGES1 expressed in CHO cells Inhibition of human recombinant mPGES1 expressed in CHO cells	[PMID: 18459759]
CHO-K1	IC₅₀	8.2 μM Compound: 1, Mk-886	Inhibition of rat mPGES-1 transfected in CHOK1 cells using [3H]PGH2 as substrate Inhibition of rat mPGES-1 transfected in CHOK1 cells using [3H]PGH2 as substrate	[PMID: 23266122]
PMNL	IC₅₀	0.09 μM Compound: 9, MK-886	Inhibition of 5-LO in PMNL cells Inhibition of 5-LO in PMNL cells	[PMID: 19053751]
RBL-2H3	IC₅₀	5 nM Compound: MK-886	The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells	[PMID: 1635053]

In Vitro

MK-886 (0.5-2 μM; 15 hours; primary keratinocytes) treatment reduces keratin-1 expression in a culture of mouse primary keratinocytes^[1].
Using a transient transfection system in monkey kidney fibroblast CV-1 cells, mouse keratinocyte 308 cells and human lung adenocarcinoma A549 cells, 10 μM MK-886 is able to inhibit Wy-14643 activation of PPARα by ~80%. MK-886 also decreases PPARα activation by fatty acids in the stable transfection system^[1].
Although Jurkat cells express all PPAR isoforms, various PPARα and PPARγ agonists are unable to prevent MK-886-induced apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Primary keratinocytes
Concentration:

0.5 µM, 1 µM or 2 µM
Incubation Time:

15 hours
Result:

Decreased in keratin-1 expression.

In Vivo

MK-886 (L 663536; 5 mg/kg; oral administration; male Sprague-Dawley rats) treatment potently inhibits the antigen-induced dyspnea in inbred rats pretreated with methysergide^[2].
MK-886 (L 663536) inhibits leukotriene biosynthesis in vivo in a rat pleurisy model (ED₅₀, 0.2 mg/kg p.o.), an inflamed rat paw model (ED₅₀, 0.8 mg/kg), a model of leukotriene excretion in rat bile following antigen provocation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats (300-400 g) with antigen-induced dyspnea^[1]
Dosage:

5 mg/kg
Administration:

Oral administration
Result:

Inhibited the antigen-induced dyspnea.

Chemical Information

CAS No. 118414-82-7
Appearance Solid
Masse moléculaire 472.08
Formule C₂₇H₃₄ClNO₂S
Color White to off-white
SMILES

CC(C)C1=CC=C(N(CC2=CC=C(Cl)C=C2)C(CC(C)(C(O)=O)C)=C3SC(C)(C)C)C3=C1
Synonyms

L 663536
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (13)

All In Vivo Efficacy StudyHistological Imaging/StainingWBIFBio/Physico-chemical AssayCell Migration/Invasion AssayRT-PCR

Sort by:

Journal Impact Factor

J Exp Clin Cancer Res

Adipocytes-induced ANGPTL4/KLF4 axis drives glycolysis and metastasis in triple-negative breast cancer. [Abstract]

2025 Jul 4;44(1):192. PMID: 40616161

MK-886 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jul 4;44(1):192. [Abstract]

Western blot analysis of PPARα and ANGPTL4 protein expression in TNBC cell lines stimulated with PA and or treated with the PPARα inhibitor MK-886 (5 µM).

MK-886 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jul 4;44(1):192. [Abstract]

Western blot analysis of PPARα, ANGPTL4, HK2, PFKP, PGK1, PGAM1, LDHA in TNBC cells cocultured with adipocytes, or treated with MK-886 (5 µM) in a co-culture system.

MK-886 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jul 4;44(1):192. [Abstract]

The OCR and ECAR levels of TNBC cells in each group were measured in TNBC cells cultured alone, co-cultured with adipocytes, or treatment of MK-886(5µM) in the co-culture system.

MK-886 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jul 4;44(1):192. [Abstract]

Transwell assay to measure the role of MK-886 treatment on the migration ability of TNBC cells induced by adipocytes.
Redox Biol

MK-886 protects against cardiac ischaemia/reperfusion injury by activating proteasome-Keap1-NRF2 signalling. [Abstract]

2023 Jun:62:102706. PMID: 37098317

MK-886 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Jun:62:102706. [Abstract]

Male mice were pretreated with MK-886 (20 mg/kg) and epoxomicin (Epox, 1 mg/kg) at 2 and 24 h before I/R-mediated cardiac injury. Echocardiographic images of the left ventricle (left). Scale bar: 0.2 s. Quantification of EF% and FS% (right, n = 6).

MK-886 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Jun:62:102706. [Abstract]

Male mice were pretreated with MK-886 (20 mg/kg) and epoxomicin (Epox, 1 mg/kg) at 2 and 24 h before I/R-mediated cardiac injury. Images of Evans blue and TTC staining (left) for infarct size analysis, with quantification of the infarction area/left ventricular (LV) area and area at risk (AAR)/LV area ratios (right; n = 6).

MK-886 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Jun:62:102706. [Abstract]

Male mice were pretreated with MK-886 (20 mg/kg) and epoxomicin (Epox, 1 mg/kg) at 2 and 24 h before I/R-mediated cardiac injury. Images of TUNEL (red), α-actinin (green), and DAPI (blue) staining of cardiac slices (left) and the percentage of TUNEL+ nuclei (right; n = 6).

MK-886 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Jun:62:102706. [Abstract]

Male mice were pretreated with MK-886 (20 mg/kg) and epoxomicin (Epox, 1 mg/kg) at 2 and 24 h before I/R-mediated cardiac injury. qPCR analysis of Bax and Bcl-2 mRNA levels in the border zone of the ischemic heart (n = 6) and quantification of the relative Bax/Bcl-2 ratio.
Genes Dev

ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease. [Abstract]

2023 Mar 1;37(5-6):204-217. PMID: 36921996
J Transl Med

KAT2B regulates estradiol synthesis via H3K27ac/PPARα in granulosa cells of PCOS patients. [Abstract]

2025 Jul 25;23(1):833. PMID: 40713779
Mol Med

Formononetin ameliorates depression-like behaviors through rebalancing microglia M1/M2 polarization and inhibiting NLRP3 inflammasome: involvement of activating PPARα-mediated autophagy. [Abstract]

2025 Apr 24;31(1):153. PMID: 40275171
Chem Biol Interact

Taurine protected As2O3-induced the activation of hepatic stellate cells through inhibiting PPARα-autophagy pathway. [Abstract]

2019 Feb 25:300:123-130. PMID: 30677399
J Mol Med (Berl)

4-Hydroxychalcone alleviated Angiotensin II-induced atrial fibrillation via immunoproteasome-IKK-NF-κB signaling pathway modulation. [Abstract]

2025 Aug 19. PMID: 40828375
iScience

Targeted inhibition of M2 macrophages polarization via a PDC attenuates chronic pancreatitis through the PPARα pathway. [Abstract]

2026 Jan 29;29(2):114839. PMID: 41716994
J Immunol Res

Respiratory Syncytial Virus Nonstructural Protein 1 Promotes 5-Lipoxygenase via miR-19a-3p. [Abstract]

2022 May 20;2022:4086710. PMID: 35637792
Hum Exp Toxicol

Effect of fenofibrate on proliferation of SMMC-7721 cells via regulating cell cycle. [Abstract]

2021 Jul;40(7):1208-1221. PMID: 33538198
J Pediatr Surg

MPGES-1 derived PGE2 inhibits cell migration by regulating ARP2/3 in the pathogenesis of Hirschsprung disease. [Abstract]

2019 Oct;54(10):2032-2037. PMID: 30814036
Patent

US20240299347A1.
Research Square Preprint

2021 Feb.

Solvant et solubilité

In Vitro:

DMSO : 75 mg/mL (158.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1183 mL

10.5914 mL

21.1828 mL

5 mM

0.4237 mL

2.1183 mL

4.2366 mL

10 mM

0.2118 mL

1.0591 mL

2.1183 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.30 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.41 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.08 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 10 mg/mL (21.18 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (284 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kehrer JP et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J. 2001 Jun 15. [Content Brief]

[2]. Gillard J et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989 May;67(5):456-64. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1183 mL	10.5914 mL	21.1829 mL	52.9571 mL
	5 mM	0.4237 mL	2.1183 mL	4.2366 mL	10.5914 mL
	10 mM	0.2118 mL	1.0591 mL	2.1183 mL	5.2957 mL
	15 mM	0.1412 mL	0.7061 mL	1.4122 mL	3.5305 mL
	20 mM	0.1059 mL	0.5296 mL	1.0591 mL	2.6479 mL
	25 mM	0.0847 mL	0.4237 mL	0.8473 mL	2.1183 mL
	30 mM	0.0706 mL	0.3530 mL	0.7061 mL	1.7652 mL
	40 mM	0.0530 mL	0.2648 mL	0.5296 mL	1.3239 mL
	50 mM	0.0424 mL	0.2118 mL	0.4237 mL	1.0591 mL
	60 mM	0.0353 mL	0.1765 mL	0.3530 mL	0.8826 mL
	80 mM	0.0265 mL	0.1324 mL	0.2648 mL	0.6620 mL
	100 mM	0.0212 mL	0.1059 mL	0.2118 mL	0.5296 mL

MK-886

13 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

MK-886

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Human Metabolite Library

Nuclear Receptor Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) MK-886

Voir tous les produits spécifiques à Isoform Leukotriene Receptor

Voir tous les produits spécifiques à Isoform PPAR

Activité biologique

Chemical Information

Publications (13)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

MK-886 Related Classifications

Cat. No.: HY-14166